Allon Therapeutics Inc NPCUF

Healthcare Biotechnology

Allon Therapeutics, Inc. is a Canada-based Company, which develops treatments for neurodegenerative diseases. The Company is engaged in pre-clinical and clinical development of proprietary neuroprotective compounds which may be applied for the potential treatment of Alzheimer's Disease, Parkinson's Disease, senile dementia, glaucoma, traumatic head injury, neuronal damage due to stroke and other conditions involving neurodegeneration. The Company's drug, davunetide, is proceeding in a pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA).

GREY:NPCUF - Post by User

Allon Therapeutics Inc

Bullboard Posts

Comment by Horn1369on Jun 19, 2013 2:27pm

180 Views

Post# 21543497

RE: RE: RE: RE: Allon will rise again

Allon Provides Update to its Proposal and Reorganization

VANCOUVER, June 7, 2013 /CNW/ - Allon Therapeutics Inc. (TSX: NPC) ("Allon" or the "Company") refers to its news release dated May 30, 2013 regarding the proposal made by the Company to its creditors pursuant to the Bankruptcy and Insolvency Act (Canada). The Company has been advised that Deloitte & Touche Inc., as proposal trustee (the "Trustee"), has received an unsolicited offer from a third party. The Company understands that the Trustee is investigating this matter and will provide updates to creditors as or when more information becomes available.

SOURCE: Allon Therapeutics Inc.

Carrie Christenson
Allon Therapeutics Inc.
(604) 736-0634
info@allontherapeutics.com
www.allontherapeutics.com